{"protocolSection": {"identificationModule": {"nctId": "NCT00214019", "orgStudyIdInfo": {"id": "H-2003-0469"}, "organization": {"fullName": "University of Wisconsin, Madison", "class": "OTHER"}, "briefTitle": "The Effect of Salmeterol on Eosinophil (EOS) Function", "officialTitle": "The Effect of Salmeterol on Eosinophil (EOS) Function"}, "statusModule": {"statusVerifiedDate": "2017-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2003-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-01", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-13", "studyFirstSubmitQcDate": "2005-09-13", "studyFirstPostDateStruct": {"date": "2005-09-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-08-17", "resultsFirstSubmitQcDate": "2016-06-24", "resultsFirstPostDateStruct": {"date": "2016-08-08", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-10-17", "lastUpdatePostDateStruct": {"date": "2017-11-21", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Wisconsin, Madison", "class": "OTHER"}, "collaborators": [{"name": "GlaxoSmithKline", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This study is designed to test the hypothesis that salmeterol use, and not fluticasone use or the combination treatment with fluticasone and salmeterol, is associated with a greater number of sputum eosinophils following antigen challenge and, under these circumstances, the migrating peripheral blood eosinophils are less adherent.", "detailedDescription": "An antigen challenge is when a participant inhales either cat, ragweed, or dust dander in increasing concentrations until their lung function drops 15 or 20 percent."}, "conditionsModule": {"conditions": ["Allergic Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["NA"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["PARTICIPANT"]}}, "enrollmentInfo": {"count": 36, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo Diskus", "type": "PLACEBO_COMPARATOR", "description": "Placebo comparator", "interventionNames": ["Drug: Placebo"]}, {"label": "Salmeterol Diskus 50 mcg twice per day", "type": "EXPERIMENTAL", "description": "Salmeterol Diskus 50 mcg twice per day", "interventionNames": ["Drug: salmeterol"]}, {"label": "Placebo diskus, fluticasone", "type": "EXPERIMENTAL", "description": "placebo diskus, fluticasone MDI 88 mcg twice per day", "interventionNames": ["Drug: Fluticasone"]}, {"label": "Salmeterol, Fluticasone", "type": "EXPERIMENTAL", "description": "Salmeterol diskus 50 mcg BID, fluticasone MDI 88 mcg twice per day", "interventionNames": ["Drug: salmeterol", "Drug: Fluticasone"]}], "interventions": [{"type": "DRUG", "name": "salmeterol", "description": "salmeterol diskus 50 mcg twice per day", "armGroupLabels": ["Salmeterol Diskus 50 mcg twice per day", "Salmeterol, Fluticasone"], "otherNames": ["Seravent", "Advair"]}, {"type": "DRUG", "name": "Fluticasone", "description": "placebo diskus, fluticasone MDI 88 mcg twice per day", "armGroupLabels": ["Placebo diskus, fluticasone", "Salmeterol, Fluticasone"], "otherNames": ["flovent", "advair"]}, {"type": "DRUG", "name": "Placebo", "description": "placebo diskus", "armGroupLabels": ["Placebo Diskus"], "otherNames": ["no drug", "comparator treatment"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge", "description": "Sputum samples were collected from the participants. Cell counts were made from these samples after treatment with 0.1% dithiothreitol. Percentage of eosinophils were reported. Time frame measurement was 24 hours after the subject had an antigen challenge.", "timeFrame": "Eosinophils are measured 24 hours after the subject has an antigen challenge"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* 18-55 years of age\n* history of asthma symptoms for the previous 6 months\n* Forced Expiratory Value (FEV1) \\>75% of predicted\n* positive prick skin test to cat, house dust mite or ragweed\n\nExclusion Criteria:\n\n* history of life threatening asthma or anaphylaxis\n* current smoker\n* pregnant or breast-feeding\n* evidence of an upper respiratory infection within 4 weeks of screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "William Busse, MD", "affiliation": "University of Wisconsin, Madison", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Wisconsin", "city": "Madison", "state": "Wisconsin", "zip": "53792", "country": "United States", "geoPoint": {"lat": 43.07305, "lon": -89.40123}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "6 participants completed all four arms of the study. 36 participants were recruited; 17 screen failed prior to randomization, 11 were lost to follow up prior to randomization, and 2 withdrew consent prior to randomization.", "recruitmentDetails": "Subjects were recruited at UW Hospital and Clinics, Madison, WI from November 2003 to January 2008.", "groups": [{"id": "FG000", "title": "All Study Participants", "description": "All participants completed all 4 arms of the study. 28 days per arm."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "36"}]}, {"type": "Placebo/Placebo Arm", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Placebo/Salmeterol Arm", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Fluticasone/Placebo Arm", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "Fluticason/Salmeterol Arm", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}, {"type": "Screen Failed prior to randomization", "reasons": [{"groupId": "FG000", "numSubjects": "17"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "This is a randomized/double-blinded/placebo-controlled/four-phase/crossover trial in subjects with a history of mild allergic asthma. Treatment arms included placebo, fluticasone 44 \u00b5g twice daily, salmeterol 50 \u00b5\u00b5g twice daily and combined FT and SA treatment, all given by inhalers. The order of these treatments was randomized for each subject.", "groups": [{"id": "BG000", "title": "4 Way Cross Over", "description": "Participants completed all 4 arms:\n\nPlacebo, Salmeterol diskus 40 mcg twice per day, Placebo then fluticasone, Salmeterol then Fluticasone,"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "6"}]}], "measures": [{"title": "Age, Categorical", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "<=18 years", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Between 18 and 65 years", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": ">=65 years", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "25.5", "spread": "6.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "3"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "3"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "6"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Sputum Eosinophils (EOS) 24 Hours Post Antigen Challenge", "description": "Sputum samples were collected from the participants. Cell counts were made from these samples after treatment with 0.1% dithiothreitol. Percentage of eosinophils were reported. Time frame measurement was 24 hours after the subject had an antigen challenge.", "populationDescription": "Participants for analysis included any subject that completed that specific treatment phase, even if they did not complete other treatment phases.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Eosinophil percentage", "timeFrame": "Eosinophils are measured 24 hours after the subject has an antigen challenge", "groups": [{"id": "OG000", "title": "Placebo/Placebo", "description": "Participants on Placebo/Placebo arm"}, {"id": "OG001", "title": "Placebo/Salmeterol", "description": "Participants on Placebo/Salmeterol arm"}, {"id": "OG002", "title": "Placebo/fFuticasone", "description": "Participants on Placebo/Fluticasone arm"}, {"id": "OG003", "title": "Salmeterol/Fluticasone", "description": "Participants on Salmeterol/Fluticasone"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}, {"groupId": "OG003", "value": "6"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.5", "spread": "3.4"}, {"groupId": "OG001", "value": "2.4", "spread": "3.4"}, {"groupId": "OG002", "value": "0.54", "spread": "0.39"}, {"groupId": "OG003", "value": "2.4", "spread": "2.6"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "2.5 years", "description": "Subject interview at visit", "eventGroups": [{"id": "EG000", "title": "4 Way Cross Over", "description": "Participants completed all 4 treatments:\n\nPlacebo Salmeterol diskus 50 mcg twice per day Placebo then Fluticasone Salmeterol then Fluticasone", "deathsNumAffected": 0, "deathsNumAtRisk": 6, "seriousNumAffected": 0, "seriousNumAtRisk": 6, "otherNumAffected": 5, "otherNumAtRisk": 6}], "otherEvents": [{"term": "Upper Respiratory Infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "ARM: Fluticasone/Placebo", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Increased asthma symptoms", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "ARM: Placebo/Salmeterol", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Back Spasm", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "ARM: Fluticasone/Salmeterol", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Scratchy throat", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "ARM: Fluticasone/Placebo", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}, {"term": "Fainted", "organSystem": "Vascular disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "ARM: Fluticasone/Placebo", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 6}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "36 subjects were screened, identifying subjects with both a peripheral eosinophil count \\>0.200x106 cells/ml and a LPR \\>15% was more difficult than expected. Of the subjects screened, only 12 met criteria and 6 subjects completed."}, "certainAgreement": {"piSponsorEmployee": true, "restrictiveAgreement": false}, "pointOfContact": {"title": "Gina Crisafi", "organization": "UW Madison", "email": "gmc@medicine.wisc.edu", "phone": "6082654554"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}, {"id": "D000068297", "term": "Fluticasone-Salmeterol Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "relevance": "LOW"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Metabolism", "relevance": "HIGH"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "asFound": "Steady state", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}